Kesselheim, A. S., Sinha, M. S., Rausch, P. et al., “Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey,” Journal of Law, Medicine & Ethics 47, no. 3 (2019): 430-441.CrossRefGoogle Scholar

U. S. Food and Drug Administration, “Drug Safety Communication: FDA Approves New Label Changes and Dosing for Zolpidem Products and a Recommendation to Avoid Driving the Day after Using Ambien CR,” May 14, 2013, available at <http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm> (last visited July 30, 2019); U.S. Food and Drug Administration, “Drug Safety Communication: Risk of Next Morning Impairment after Use of Insomnia Drugs; FDA Requires Lower Recommended Doses fo Certain Drugs Containing Zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist),” January 10, 2013, available at <https://www.fda.gov/media/84992/download> (last visited July 30, 2019).+(last+visited+July+30,+2019);+U.S.+Food+and+Drug+Administration,+“Drug+Safety+Communication:+Risk+of+Next+Morning+Impairment+after+Use+of+Insomnia+Drugs;+FDA+Requires+Lower+Recommended+Doses+fo+Certain+Drugs+Containing+Zolpidem+(Ambien,+Ambien+CR,+Edluar,+and+Zolpimist),”+January+10,+2013,+available+at++(last+visited+July+30,+2019).>Google Scholar

U. S. Food and Drug Administration, Drug Safety Communication: FDA Warns of Next-Day Impairment with Sleep Aid Lunesta (eszopiclone) and Lowers Recommended Dose,” May 15, 2014, available at <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-next-day-impairment-sleep-aid-lunesta-eszopicloneand-lowers> (last visited July 30, 2019).+(last+visited+July+30,+2019).>Google Scholar

Kesselheim, A. S., McGraw, S. A., Dejene, S. Z., et al., “Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study,” Drug Safety 40, no. 6 (2017): 531-542.CrossRefGoogle Scholar

See Kesselheim, et. al., supra note 1.Google Scholar

Kesselheim, A. S., Campbell, E. G., Schneeweiss, S., et al., “Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications,” Drug Safety 38, no. 6 (2015): 565-575.CrossRefGoogle Scholar

Kesselheim, A. S., Donneyong, M., Dal Pan, G. J., et al., “Changes in Prescribing and Healthcare Resource Utilization after FDA Drug Safety Communications Involving Zolpidem-Containing Medications,” Pharmacoepidemiology & Drug Safety 26, no. 6 (2017): 712-721.Google Scholar

Dusetzina, S. B., Higashi, A. S., Dorsey, E. R., et al., “Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review,” Medical Care 50, no. 6 (2012): 466-478.CrossRefGoogle Scholar

Piening, S., “Impact of Safety-Related Regulatory Action on Drug Use in Ambulatory Care in the Netherlands,” Clinical Pharmacology and Therapeutics 91, no. 5 (2012): 838-845.CrossRefGoogle Scholar

Hugman, B. and Edwards, I. R., “The Challenge of Effectively Communicating Pateint Safety Information,” Expert Opinion on Drug Safety 5, no. 4 (2006): 495-599.CrossRefGoogle Scholar

See Kesselheim et al., supra note 1.Google Scholar

Schwartz, L. M. and Woloshin, S., “Medical Marketing in the United States, 1997-2016,” JAMA 321, no. 1 (2019): 80-96.CrossRefGoogle Scholar

Community Catalyst Blog, “Bitter Pill Award Winner Lunesta has Most Recalled Drug Ad,” June 15, 2007, available at <https://www.communitycatalyst.org/blog/bitter-pill-award-winner-lunesta-has-most-recalled-drug-ad-pal#.XNUZ3NM-zaRs> (last visited July 30, 2019).+(last+visited+July+30,+2019).>Google Scholar

Huedo-Medina, T. B., Kirsch, I., Middlemass, J., et al., “Effectiveness of Non-Benzodiazepine Hypnotics in Treatment of Adult Insomnia: Meta-Analysis of Data Submitted to the Food and Drug Administration,” BMJ 345 (2012): e8343, doi: http://dx.doi.org/10.1136/bmj.e8343.CrossRefGoogle Scholar

Rösner, S., Englbrecht, C., Wehrle, R., et al., “Eszopiclone for Insomnia, Cochrane Database of Systematic Reviews 10 (2018): Art. No.: CD010703, doi: http://dx.doi.org/10.1002/14651858.CD010703pub2.Google ScholarPubMed

Lundh, A., Lexchin, J., Mintzes, B., et al., “Industry Sponsorship and Research Outcome,” Cochrane Database of Systematic Reviews 2 (2017): Art. No.: MR000033, doi: http://dx.doi.org/10.1002/14651858.MR000033.pub3.Google Scholar

UK National Institute of Clinical Excellence, “Hypnotics: Key Therapeutic Topics,” January 15, 2015, available at <https://www.nice.org.uk/advice/ktt6> (last visited July 30, 2019).+(last+visited+July+30,+2019).>Google Scholar

UK National Institute of Clinical Excellence, “Guidance on the Use of Zaleplon, Zolpidem and Zopiclone for the Shortterm Management of Insomnia,” (2004), available at <https://www.nice.org.uk/guidance/ta77/resources/guidance-on-theuse-of-zaleplon-zolpidem-and-zopiclone-for-the-shortterm-management-of-insomnia-pdf-2294763557317> (last visited July 30, 2019).+(last+visited+July+30,+2019).>Google Scholar

Pinto, L. R. Jr., Bittencourt, L. R. A., Treptow, E. C., et al., “Eszopiclone Versus Zopiclone in the Treatment of Insomnia,” Clinics 71, no. 1 (2016): 5-9.CrossRefGoogle Scholar

See Kesselheim et al., supra note 1.Google Scholar

European Medicines Agency, “Pharmacovigilance Risk Assessement Committee (PRAC), PRAC Strategy on Measuring the Impact of Pharmacovigilance Activities (Rev 1),” November 30, 2017, available at <https://www.ema.europa.eu/en/documents/other/prac-strategy-measuring-impact-pharmaco-vigilance-activities_en.pdf> (last visited July 30, 2019).+(last+visited+July+30,+2019).>Google Scholar

U. S. Food and Drug Administration, “Drug Safety Communication: FDA adds Boxed Warning for Risk of Serious Injuries Caused by Sleepwalking with Certain Prescription Insomnia Medicines,” April 30, 2019, available at <https://www.fda.gov/media/123819/download> (last visited July 30, 2019).+(last+visited+July+30,+2019).>Google Scholar